Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Nasopharyngeal Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrence 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Breast Neoplasms 1Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer 1Advanced Malignant Tumors 1

Interventions

Injections 4apatinib 3Cisplatin 3Capecitabine 3toripalimab 2alpha-Synuclein 2Oxaliplatin 2Gemcitabine 2Drug Therapy 2Docetaxel 2trametinib 1tislelizumab 1tesetaxel 1surufatinib 1spartalizumab 1pyrotinib 1pemigatinib 1pembrolizumab 1nimotuzumab 1mogamulizumab 1irinotecan sucrosofate 1fludarabine 1famitinib 1dalpiciclib 1camrelizumab 1YM753 compound 1Vemurafenib 1Taxes 1SHR-1701 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Solid Tumor × SHR-1701 × Clear all
NCT04679038 2022-01-26

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
222 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡